Sibeprenlimab

sibeprenlimab

Subcutaneous antibody given every four weeks that blocks APRIL. US FDA accelerated approval (25 November 2025) to reduce proteinuria in adults with primary IgA nephropathy at risk of progression; slowing of kidney function decline not established in the label. Final two-year phase 3 VISIONARY results published October 2026; supplemental application for traditional approval submitted.